Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Historic company milestone reached in 1st US FDA approval of cannabidiol.
For investors/media, click here for more

Recent News

Aug 28, 2018
Vienna, Austria, 28 August 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescription medicines, presents a variety of data on cannabidiol oral solution (CBD) at the 13th Annual European Congress of Epileptology (ECE), taking place in Vienna, Austria from 26-30 August
Aug 07, 2018
- Epidiolex® (cannabidiol) oral solution approved by FDA and on track to be launched in Fall - - Conference call today at 4:30 p.m. EST -  
Jul 23, 2018
London, UK, 23 July 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2018 its third quarter financial results for the period ending 30 June, 2018.

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Approved
Epidiolex
Lennox-Gastaut Syndrome
Approved
Epidiolex
Tuberous Sclerosis
Phase 3

Sativex (U.S.)

Sativex
Ms Spasticity
Phase 3

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Completed Phase 1

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioblastoma
Completed Phase 2
GWP42003
Schizophrenia
Completed Phase 2